Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 20/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 19/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 17/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 17/20 | 1.00 |
| ▸ | FLT3 | P36888 | 8/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12178753 | 0.97 | FGFR3 (1.00) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL2581586 | 0.94 | FGFR3 (1.00) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL12178480 | 0.92 | FGFR3 (0.98) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL18176258 | 0.92 | FGFR3 (0.89) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL12178338 | 0.92 | FGFR3 (0.84) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL12178845 | 0.91 | FGFR3 (0.87) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL18176306 | 0.91 | FGFR3 (0.88) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL12178453 | 0.91 | FGFR3 (1.00) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL12178567 | 0.91 | FGFR3 (0.85) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL12178515 | 0.91 | FGFR3 (0.89) | FGFR3KDRFGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| US-20200131153-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2020-04-30 | — | — | US | disclosed |
| US-20200131153-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2020-04-30 | — | — | US | disclosed |
| EP-3178818-B1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2019-05-22 | — | — | EP | disclosed |
| US-20180127397-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180127397-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180127397-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-9850228-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20150105368-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-04-16 | — | — | US | disclosed |
| US-8895601-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895601-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895601-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-21 | — | — | US | disclosed |
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-21 | — | — | US | disclosed |
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-21 | — | — | US | disclosed |
| EP-2563775-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011135376-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011135376-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131153-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | FGFR3 2685/4885KDR 1145/4885FGFR1 1681/4885 |
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | MAP3K5, MAP3K1, MAP4K2 | FGFR3 2031/4885KDR 988/4885FGFR1 1333/4885 |
| US-20150105368-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | FGFR3 2685/4885KDR 1145/4885FGFR1 1681/4885 |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | FGFR3 13/4885KDR 5/4885FGFR1 1/4885 |
| US-20180127397-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | FGFR3 2685/4885KDR 1145/4885FGFR1 1681/4885 |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | FGFR3 2685/4885KDR 1145/4885FGFR1 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.